Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | MITF | O75030 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | XBP1 | P17861 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18946294 | 0.84 | LMNA (0.40) | LMNAMAPTALDH1A1CSNK1DPOLB | |
| SCHEMBL30133893 | 0.84 | MAPT (0.40) | LMNAARMAPTMITFALDH1A1 | |
| SCHEMBL21054420 | 0.83 | LMNA (0.39) | LMNAMAPTALDH1A1CSNK1DL3MBTL1 | |
| SCHEMBL1074409 | 0.82 | LMNA (0.38) | LMNAMAPTALDH1A1CSNK1DL3MBTL1 | |
| SCHEMBL29600809 | 0.82 | LMNA (0.38) | LMNAMAPTALDH1A1CSNK1DL3MBTL1 | |
| SCHEMBL21621425 | 0.81 | LMNA (0.38) | LMNAMAPTALDH1A1CSNK1DNPSR1 | |
| SCHEMBL25465376 | 0.81 | LMNA (0.39) | LMNAMAPTALDH1A1CSNK1DNPSR1 | |
| SCHEMBL14136588 | 0.81 | CSNK1D (0.39) | LMNAMAPTALDH1A1CSNK1DNPSR1 | |
| SCHEMBL18209791 | 0.80 | KDM4E (0.37) | LMNACSNK1DKDM4ENPC1RAB9A | |
| SCHEMBL22235605 | 0.79 | ELANE (0.39) | LMNAALDH1A1CSNK1DPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714697-B1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-9079919-B2 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8598200-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120302549-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302549-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN1 | LMNA 2196/4885AR 1022/4885MAPT 123/4885 |
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | LMNA 3069/4885AR 4043/4885MAPT 126/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | LMNA 3069/4885AR 4043/4885MAPT 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.